Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy
- Ryuzo Ohno MD, PhD
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The presence of the Philadelphia chromosome (Ph) is associated with a very poor prognosis in acute lymphoblastic leukemia (ALL). Although hematologic complete remission (CR) is achieved in 50% to 80% of adult patients by intensive chemotherapy in multicenter studies, long-term outcome is dismal, with overall survival of approximately 10%. Currently, allogeneic hematopoietic stem cell transplantation (allo-SCT) is thought to be the only curative therapeutic modality for this leukemia in adults, but the long-term survival rates are about 40% or less, far from satisfactory. Imatinib mesylate, a recently introduced specific tyrosine kinase inhibitor of BCR-ABL, in combination with chemotherapy, resulted in more than 90% hematologic CR in adult Ph-positive ALL, including molecular CR in more than 50% of patients. The higher CR rate and less frequent relapse gave more patients a chance to receive SCT. Patients who did not qualify for allo-SCT because of the lack of a suitable donor, advanced age, or underlying medical conditions apparently showed better survival than historical control patients treated with chemotherapy alone. Although longer follow-up is required to determine the effect on survival, imatinib in combination with chemotherapy clearly has a major potential to improve the treatment of Ph-positive ALL and may cure a substantial proportion of patients without SCT.
- Hermans A, Heisterkamp N, von Linden M, et al.: Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987, 51:33–40. CrossRef
- Chan LC, Karhi KK, Rayter SI, et al.: A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987, 325:635–637. CrossRef
- Clark SS, McLaughlin J, Timmons M, et al.: Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988, 239:775–777. CrossRef
- Lugo TG, Pendergast AM, Muller AJ, et al.: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079–1082. CrossRef
- Faderl S, Kantarjian HM, Talpaz M, et al.: Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998, 91:3995–4019.
- Jones LK, Saha V: Philadelphia positive acute lymphoblastic leukaemia of childhood. Brit J Haematol 2005, 130:489–500. CrossRef
- Groupe Français de Cytog’en’etique H’ematologique:Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Group Français de Cytog’en’etique H’ematologique. Blood 1996, 87:3135–3142.
- Wetzler M, Dodge RK, Mrozek K, et al.: Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999, 93:3983–3993.
- Faderl S, Kantarjian HM, Thomas DA, et al.: Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000, 36:263–273. CrossRef
- Thomas X, Danaila C, Le QH, et al.: Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001, 15:1811–1822.
- Dombret H, Gabert J, Boiron JM, et al.: Outcome of treatment in adults with Philadelphia chromosomepositive acute lymphoblastic leukemia—results of the prospective multicenter L AL A-94 trial. Blood 2002, 100:2357–2366. CrossRef
- Gleissner B, Gökbuget N, Bartram CR, et al.: Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002, 99:1536–1543. CrossRef
- Takeuchi J, Kyo T, Naito K, et al.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002, 16:1259–1266. CrossRef
- Rowe JM, Buck G, Burnett AK, et al.: Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UK ALL XII/ECOG E2993. Blood 2005, 106:3760–3767. CrossRef
- Barrett AJ, Horowitz MM, Ash RC, et al.: Bone marrow transplantation for Philadelphia chromosomepositive acute lymphoblastic leukemia. Blood 1992, 79:3067–3070.
- Goldstone AH, Prentice HG, Durrant IJ, et al.: Allogeneic transplant (related or unrelated donor) is the preferred treatment for adult Philadelphia chromosome positive (Ph) acute lymphoblastic leukaemia (ALL): results from the International ALL Trial (MRC UKALLXII/ECOG E2993) [abstract]. Blood (ASH Annual Meeting Abstracts) 2001, 98:856a.
- Cornelissen JJ, Carston M, Kollman C, et al.: Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001, 97:1572–1577. CrossRef
- Avivi I, Goldstone AH: Bone marrow transplant in Ph+ ALL patients [review]. Bone Marrow Transplant 2003, 31:623–632. CrossRef
- Iida H, Sao H, Kitaori K, et al.: Twenty years’ experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol 2004, 79:79–84. CrossRef
- Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407.The first paper reporting a 100% CR rate by imatinib in combination with chemotherapy in 15 adults with Ph-positive ALL from a single center. They previously reported a 90% CR rate by the ver y intensive hyper-CVAD chemotherapy alone, however, so the role of imatinib was not convincing in a small number of patients, and the long-term prognosis of the patients treated with hyper-CVAD was ver y poor. CrossRef
- Tanimoto M, Miyawaki S, Ino T, et al.: Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG). Int J Hematol 1998, 68:421–429. CrossRef
- Ueda T, Miyawaki S, Asou N, et al.: Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998, 68:279–289. CrossRef
- Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on growth of Bcr-Abl positive cells. Nat Med 1996, 2:561–566. CrossRef
- Deininger MW, Goldman MJ, Lydon N, Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997, 90:3691–3698.
- Gambacorti-Passerini C, le Coutre P, Mologni L, et al.: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997, 23:380–394. CrossRef
- O’Brien SG, Guilhot F, Larson R A, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994–1004. CrossRef
- Kantarjian HM, O’Brien S, Cortes J, et al.: Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003, 98:2636–2642. CrossRef
- Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042. CrossRef
- Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965–1971. CrossRef
- Kano Y, Akutsu M, Tsunoda S, et al.: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001, 97:1999–2007. CrossRef
- Towatari M, Yanada M, Usui N, et al.: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004, 104:3507–3512.The first paper reporting a 96% CR rate from a multicenter study group by imatinib in combination with chemotherapy in 24 adults with Ph-positive ALL. An updated result is reported in reference 32. CrossRef
- Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460–466.Updated results for the study in reference 31•, reporting a 97% complete remission rate with use of imatinib in combination with chemotherapy in 80 adults with Ph-positive ALL. Although the follow-up period is still very short, the overall survival of 31 non-transplant patients is more than 60%, indicating that adult Ph-positive ALL may be curable by imatinib in combination wit ch emotherapy without stem cell transplantation. CrossRef
- Thomas DA, Faderl S, Cortes J, et al.: Outcome with the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:521a. Abstract 1830.
- Wassmann B, Pfeifer H, Gökbuget N, et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2006, Epub ahead of print. Another paper reporting a 95% CR rate from a multicenter study in 92 newly diagnosed patients. Findings show that a concurrent administration schedule of imatinib and chemotherapy is better than alternating administration when compared by prognosis.
- Kantarjian HM, Talpaz M, O’Brien S, et al.: Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003, 101:473–475. CrossRef
- O’Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500–4505. CrossRef
- Kimura S, Naito H, Segawa H, et al.: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106:3948–3954. CrossRef
- Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy
Current Hematologic Malignancy Reports
Volume 1, Issue 3 , pp 180-187
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Aichi Cancer Center and Aichi Syukutoku University, Chikusaku, 464-8681, Nagoya, Japan